NASDAQ:SNOA

Sonoma Pharmaceuticals (SNOA) Stock Price, News & Analysis

$0.16
0.00 (-1.00%)
(As of 09:04 AM ET)
Today's Range
$0.16
$0.16
50-Day Range
$0.13
$0.18
52-Week Range
$0.12
$1.52
Volume
7,223 shs
Average Volume
1.62 million shs
Market Capitalization
$2.47 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$3.25

Sonoma Pharmaceuticals MarketRank™ Stock Analysis

Analyst Rating
Buy
3.00 Rating Score
Upside/​Downside
1,951.8% Upside
$3.25 Price Target
Short Interest
Healthy
0.19% of Shares Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
N/A
Insider Trading
N/A
Proj. Earnings Growth
Growing
From ($0.89) to ($0.45) Per Share

Overall MarketRank

New Rank-Based ScoringMarketRank is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

2.27 out of 5 stars

SNOA stock logo

About Sonoma Pharmaceuticals Stock (NASDAQ:SNOA)

Sonoma Pharmaceuticals, Inc., develops and produces stabilized hypochlorous acid (HOCl) products for wound care, animal health care, eye care, oral care, and dermatological conditions in the United States, Latin America, Europe, Asia, and internationally. The company offers Regenacyn, a prescription scar gel; Pediacyn, a pediatric dermatology and wound care product for over-the-counter (OTC) use; Epicyn, an Antimicrobial Facial Cleanser; Levicyn, an HOCl based prescription and OTC product to use and relieve skin irritations, lacerations, abrasions, and burns; Celacyn, a scar management gel; and SebuDerm to manage and relieve the burning, itching, erythema, scaling, and pain associated with seborrhea and seborrheic dermatitis. It also provides Gramaderm for the treatment of topical mild to moderate acne; Microcyn, a HOCl-based topical line of products designed to stimulate expedited healing by targeting a wide range of pathogens; Ocucyn eyelid and eyelash cleanser; Microdacyn60 oral care solution for the treatment of mouth and throat infections; and Podiacyn, a foot care product. In addition, the company offers MicrocynAH, an HOCl-based solution designed to relieve common symptoms of hot spots, scratches, skin rashes post-surgical sites, and irritated animal skin for healing; MicrocynVS, a veterinarian-strength animal care product used in vet clinics and animal hospitals; Nanocyn, a hospital-grade disinfectant; Acuicyn, an antimicrobial prescription solution for the treatment of blepharitis and the daily hygiene of eyelids and lashes; MucoClyns for the use in emergencies and safe to use on mucous membranes, cuts, abrasions, burns, and body surfaces; Endocyn root canal irrigation solutions; and Sinudox for nasal irrigation. The company was formerly known as Oculus Innovative Sciences, Inc. and changed its name to Sonoma Pharmaceuticals, Inc. in December 2016. Sonoma Pharmaceuticals, Inc. was incorporated in 1999 and is based in Boulder, Colorado.

SNOA Stock Price History

SNOA Stock News Headlines

top AI stock (it’s not MSFT, GOOGL, AMZN or AAPL)
AI was by far the biggest tech investing trend right now. But Ross Givens says the #1 artificial intelligence stock[/lin] is NOT Microsoft, Google, Amazon or Apple. Nope — his research is pointing to a tiny, under-the-radar stock that’s trading for just a few dollars right now… And could soon shoot to the moon, handing early investors a windfall.
top AI stock (it’s not MSFT, GOOGL, AMZN or AAPL)
AI was by far the biggest tech investing trend right now. But Ross Givens says the #1 artificial intelligence stock[/lin] is NOT Microsoft, Google, Amazon or Apple. Nope — his research is pointing to a tiny, under-the-radar stock that’s trading for just a few dollars right now… And could soon shoot to the moon, handing early investors a windfall.
Sonoma Pharmaceuticals Inc SNOA
Crude Oil Down 2.5%; Mastercard Posts Upbeat Earnings
macOS Sonoma
See More Headlines
Receive SNOA Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Sonoma Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
2/08/2024
Today
4/25/2024
Next Earnings (Estimated)
6/19/2024
Fiscal Year End
3/31/2025

Industry, Sector and Symbol

Sector
Medical
Industry
Pharmaceutical preparations
Sub-Industry
N/A
Current Symbol
NASDAQ:SNOA
Employees
9
Year Founded
1999

Price Target and Rating

Average Stock Price Target
$3.25
High Stock Price Target
$3.25
Low Stock Price Target
$3.25
Potential Upside/Downside
+1,951.8%
Consensus Rating
Buy
Rating Score (0-4)
3.00
Research Coverage
1 Analysts

Profitability

Net Income
$-5,150,000.00
Pretax Margin
-41.53%

Debt

Sales & Book Value

Annual Sales
$13.27 million
Book Value
$1.72 per share

Miscellaneous

Free Float
14,171,000
Market Cap
$2.47 million
Optionable
Not Optionable
Beta
1.28

Social Links

Metaverse Stocks And Why You Can't Ignore Them Cover

Thinking about investing in Meta, Roblox, or Unity? Click the link to learn what streetwise investors need to know about the metaverse and public markets before making an investment.

Get This Free Report

Key Executives

  • Ms. Amy M. Trombly (Age 56)
    CEO, President & Director
    Comp: $524.19k
  • Mr. Jerome J. Dvonch (Age 56)
    Chief Financial Officer
    Comp: $281.16k
  • Mr. Bruce Thornton (Age 60)
    COO & Corporate Secretary
    Comp: $448.87k
  • Mr. John Dal Poggetto (Age 52)
    Controller
    Comp: $433.36k

SNOA Stock Analysis - Frequently Asked Questions

Should I buy or sell Sonoma Pharmaceuticals stock right now?

1 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Sonoma Pharmaceuticals in the last year. There are currently 1 buy rating for the stock. The consensus among Wall Street research analysts is that investors should "buy" SNOA shares.
View SNOA analyst ratings
or view top-rated stocks.

What is Sonoma Pharmaceuticals' stock price target for 2024?

1 Wall Street analysts have issued 12-month price objectives for Sonoma Pharmaceuticals' shares. Their SNOA share price targets range from $3.25 to $3.25. On average, they predict the company's stock price to reach $3.25 in the next twelve months. This suggests a possible upside of 1,951.8% from the stock's current price.
View analysts price targets for SNOA
or view top-rated stocks among Wall Street analysts.

How have SNOA shares performed in 2024?

Sonoma Pharmaceuticals' stock was trading at $0.1804 at the beginning of the year. Since then, SNOA stock has decreased by 12.2% and is now trading at $0.1584.
View the best growth stocks for 2024 here
.

Are investors shorting Sonoma Pharmaceuticals?

Sonoma Pharmaceuticals saw a decrease in short interest in the month of March. As of March 31st, there was short interest totaling 30,400 shares, a decrease of 74.2% from the March 15th total of 117,800 shares. Based on an average trading volume of 1,920,000 shares, the short-interest ratio is presently 0.0 days.
View Sonoma Pharmaceuticals' Short Interest
.

When is Sonoma Pharmaceuticals' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Wednesday, June 19th 2024.
View our SNOA earnings forecast
.

How were Sonoma Pharmaceuticals' earnings last quarter?

Sonoma Pharmaceuticals, Inc. (NASDAQ:SNOA) announced its quarterly earnings data on Thursday, February, 8th. The company reported ($0.06) EPS for the quarter, topping analysts' consensus estimates of ($0.21) by $0.15. The firm had revenue of $3.14 million for the quarter. Sonoma Pharmaceuticals had a negative trailing twelve-month return on equity of 58.93% and a negative net margin of 41.24%.

What other stocks do shareholders of Sonoma Pharmaceuticals own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Sonoma Pharmaceuticals investors own include Inovio Pharmaceuticals (INO), VelocityShares Daily 2x VIX Short-Term ETN (TVIX), Sorrento Therapeutics (SRNE), Bristol-Myers Squibb (BMY), Gilead Sciences (GILD), Amarin (AMRN), Pfizer (PFE), Nabriva Therapeutics (NBRV), Verastem (VSTM) and Vaxart (VXRT).

How do I buy shares of Sonoma Pharmaceuticals?

Shares of SNOA stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NASDAQ:SNOA) was last updated on 4/25/2024 by MarketBeat.com Staff

From Our Partners